Nishi, Ryotaro
Wijnhoven, Paul
le Sage, Carlos
Tjeertes, Jorrit
Galanty, Yaron
Forment, Josep V.
Clague, Michael J.
Urbé, Sylvie
Jackson, Stephen P.
Article History
Received: 8 May 2014
Accepted: 11 July 2014
First Online: 7 September 2014
Competing interests
: S.P.J. is a founder and shareholder of MISSION Therapeutics Ltd., which is developing DUB inhibitors for therapeutic applications. The other authors declare no competing financial interests.